Latest News

NCCN adds mammogram AI risk scoring; a 1.7% five‑year cutoff now prompts earlier screening and optional MRI/ultrasound.

Naomi Haas, MD, shares her insights on the rapidly shifting landscape of adjuvant and neoadjuvant therapies in renal cell carcinoma.

FDA reviews new zenocutuzumab bid for NRG1 fusion cholangiocarcinoma and NCCN adds new recommendations for use of the bispecific antibody.

The FDA granted FTD to OPN-6602, an oral EP300/CBP inhibitor currently used in a first-in-human phase 1 trial.

Tisotumab vedotin plus carboplatin and pembrolizumab ± bevacizumab elicited antitumor acitivity in a phase 1/2 cervical cancer trial.

During a live event, Mark Yarchoan, MD and participants weighed new phase 3 immunotherapy combos for unresectable HCC, balancing survival gains, response durability, and real‑world toxicity challenges.

New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying targeted treatment decisions.

Daraxonrasib nearly doubled median OS vs chemotherapy in pretreated metastatic pancreatic cancer, per phase 3 RASolute 302 trial data.

Community oncology practices can deliver chimeric antigen receptor (CAR) T-cell therapy safely, effectively, and in a sustained manner.

FDA grants priority review to ifinatamab deruxtecan for extensive-stage SCLC based on phase 2 IDEATE-Lung01 data. PDUFA date set for October 10, 2026.

AZD0120, a rapidly manufactured CAR T product, was used successfully in a small number of patients with multiple myeloma with older age and frailty.

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The first patient has been dosed in a phase 1 trial (NCT05997615) of VIR-5500, a dual-masked PSMA-targeting T-cell engager for metastatic prostate cancer.

The DAISY trial shows that HER2DX and DNADX genomic assays can predict T-DXd response in metastatic breast cancer by measuring HER2 levels and DNA instability.

FDA accepted the NDA for 18F-FET, a PET imaging agent designed to distinguish glioma progression from treatment-induced changes in brain cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with HER2-expressing endometrial cancer.

Final ROSELLA overall survival results show adding relacorilant to nab-paclitaxel reduces risk of death by 35% in platinum-resistant ovarian cancer.

Breast cancer surgery myths, new ALK lung drug filing, safer TIL melanoma prep, ovarian ADC fast track, and statins boosting CAR T outcomes.

During a live event, Carol Ann Huff, MD, and participants discussed real-world evidence and personal experiences with talquetamab in relapsed/refractory multiple myeloma.

The FDA did not grant accelerated approval to the oncolytic virus-based therapy RP1 in combination with nivolumab for patients with advanced melanoma.

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians.

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and safety notes.

FDA grants fast track designation to SIM0505, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. Phase 1 data expected at ASCO 2026.

Tovecimig plus paclitaxel lifts response rates in second-line biliary tract cancer, prompting FDA orphan status and advancing a potential new option.

The FDA has granted fast track and rolling review status to Celltrion’s CT-P71, a Nectin-4 targeting ADC for treating advanced urothelial carcinoma.

FDA grants orphan drug designation to rhenium (186Re) obisbemeda for pediatric glioma and ependymoma, supported by the phase 1/2a ReSPECT-PBC clinical trial.

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.

During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including eligibility and eased REMS rules.

The FDA has agreed on the design of two phase 3 trials of the antibody-drug conjugate CRB-701 in HNSCC and cervical cancer.

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ALK-positive NSCLC.